NCI, FNLCR Help Launch Pediatric MATCH Precision Medicine Trial
The National Cancer Institute and Children’s Oncology Group recently opened enrollment for a new Phase II trial of personalized precision cancer therapies. Called the Pediatric Molecular Analysis for Therapy Choice (Pediatric MATCH), the trial seeks to treat children and adolescents aged 1–21 whose solid tumors have failed to respond to or re-emerged after traditional cancer treatments.